Заболевания поджелудочной железы и терапия
Открытый доступ

Абстрактный

Испытание II этапа капецитабина в сочетании с талидомидом в качестве терапии второй линии при прогрессирующем росте поджелудочной железы

Ши Шэнбинь, Ван Мэн, Ню Цзо-син, Тан Сяоюн и Цюань Юнь-Лю

Abstract Background: To assess the viability and averageness of capecitabine joined together with thalidomide in patients with propelled pancreatic disease (APC) who have beforehand accepted gemcitabine-based treatment. Systems: what added up to 31 patients were enrolled prospectively in Shandong Tumor Hospital from May 2007 to April 2009. Capecitabine was offered to patients twice a day at a dosage of 1,250 mg/m2 for 14-days then emulated by 7-day rest. Thalidomide was controlled 100 mg/day without interference until sickness movement or event of inadmissible poisonous quality. Results: Two patients put forth fractional reaction (PR), eleven patients indicated stable ailment (SD) and eighteen patients exhibited continuous illness (PD). The average without movement survival (PFS) was 2.7 months (95% expectancy interim (CI), 2.4-3.3) and the average generally speaking survival (OS) was 6.1 months (95% CI, 5.3-6.9). In the subgroup examination, PFS had a huge distinction between the serum CA19-9 level diminishing >25% and diminishing <25%, with 3.0 months (95% CI, 2.5-3.6) and 2.5 months (95% CI, 1.8-3.2), (Log Rank=0.02), separately. Hematological poisonous quality incorporated leukocytopenia, frailty and neutropenia. Non-hematological toxicities incorporated loose bowels, skin rash, nausea/vomiting, hand-foot syndrome, weariness, discombobulation, languor and clogging. Conclusion: Capecitabine joined together with thalidomide is a generally tolerated second line regimen, in patients with APC obstinate to gemcitabine.